Compositions for the treatment and prophylaxis of metabolic disturbances in infants
CA 2105881 A1 · Owner: Serfontein, Willem Jacob · Inventors: Serfontein, Willem Jacob
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Treatment or prophylaxis of depressed or inadequate intracellular pyridoxal phosphate levels in a human or animal patient resulting from a condition wherein, the pyridoxine (PN) - pyridoxal phosphate (PLP) pathway is disturbed by cellulardefects and concomitant enzyme deficiences. These may be due to genetic causes or cell immaturity, as occurs in infants and in diseases resulting in erythrocytes destruction. In infants it was found, for the first time that this leads to elevated, homocysteine levels. The deficiencies are counteracted by the administration of pyridoxal or a precursor of pyridoxal which in vivo, once it has entered the bloodstream is rapidly converted into, pyridoxal without …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 13, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 13, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 13, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.